Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts
Climb Bio announces significant progress in the development of budoprutug, an anti-CD19 monoclonal antibody targeting B-cell mediated immune diseases. Positive topline Phase 1 data shows robust B-cell depletion via a subcutaneous formulation, supporting advancement to patient trials. Clinical trials for primary membranous nephropathy, immune thromb…